Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.

Emilie DucourauTheo RispensMarine SamainEmmanuelle DernisFabienne Le GuilchardLucia AndrasAleth PerdrigerEric LespessaillesAntoine MartinGrégoire CormierThomas ArmingeatValérie Devauchelle-PensecElisabeth GervaisBenoit Le GoffAnnick de VriesEric PiverGilles PaintaudCéline DesvignesDavid TernantHervé WatierPhilippe GoupilleDenis Mulleman

Published in: RMD open (2020)

MTX reduces the immunogenicity and ameliorate the pharmacokinetics of adalimumab in axial SpA. A prolonged co-treatment of MTX>W26 seems to increase adalimumab long-term maintenance.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
hidradenitis suppurativa
disease activity
ulcerative colitis
ankylosing spondylitis
high dose
study protocol
open label
low dose
randomized controlled trial